Influence of rs5065 Atrial Natriuretic Peptide Gene Variant on Coronary Artery Disease. by Barbato E et al.
Journal of the American College of Cardiology Vol. 59, No. 20, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00Cardiovascular Risk
Influence of rs5065 Atrial Natriuretic
Peptide Gene Variant on Coronary Artery Disease
Emanuele Barbato, MD, PHD,* Jozef Bartunek, MD, PHD,* Fabio Mangiacapra, MD, PHD,*
Sebastiano Sciarretta, MD,† Rosita Stanzione, PHD,† Leen Delrue, PHD,* Maria Cotugno, PHD,†
Simona Marchitti, PHD,† Guido Iaccarino, MD,‡ Giusy Sirico, MD,‡ Sara Di Castro, PHD,†
Anna Evangelista, PHD,† Diether Lambrechts, MD, PHD,§ Peter Sinnaeve, MD, PHD,¶
Bernard De Bruyne, MD, PHD,* Frans Van De Werf, MD, PHD,¶ Stefaan Janssens, MD, PHD,¶
Keith A. A. Fox, MD, PHD,# William Wijns, MD, PHD,* Massimo Volpe, MD,†**
Speranza Rubattu, MD†**
Aalst and Leuven, Belgium; Pozzilli, Salerno, and Rome, Italy; and Edinburgh, United Kingdom
Objectives The aim of this study was to investigate the impact of rs5065 atrial natriuretic peptide (ANP) gene variant on coro-
nary artery disease (CAD) and its outcomes and to gain potential mechanistic insights on the association with CAD.
Background Either modified ANP plasma levels or peptide structural alterations have been involved in development of
cardiovascular events.
Methods Three hundred ninety-three control subjects and 1,004 patients undergoing coronary angiography for suspected
CAD (432 stable angina [SA], 572 acute coronary syndrome [ACS]) were genotyped for rs5065 ANP gene vari-
ant. Data in SA and ACS groups were replicated in an independent population of 482 stable angina patients
(rSA) and of 675 ACS patients, respectively. Clinical follow-up was available for both SA and rSA patients.
Plasma N-terminal-proANP, myeloperoxidase, lipoprotein-associated phospholipase A2, and oxidized low-density
lipoprotein were assessed in a subgroup of rSA patients.
Results rs5065 minor allele (MA) was an independent predictor of ACS (odds ratio: 1.90; 95% confidence interval: 1.40
to 2.58, p  0.001). At follow-up, rs5065 MA was independently associated with a significantly higher rate of
major adverse cardiovascular events in the SA group, p  0.001. Data were replicated in the rSA group at
follow-up (p  0.008). Cox proportional hazard analysis tested by 4 models confirmed higher major adverse car-
diovascular events risk in rs5065 MA carriers in both SA and rSA cohorts. Significantly higher myeloperoxidase
levels were detected in rs5065 MA carriers (n  597 [345 to 832 g/l] vs. n  488 [353 to 612 g/l], p 
0.038). No association of rs5065 was observed with N-terminal-proANP levels.
Conclusions The MA of rs5065 ANP gene variant associates with increased susceptibility to ACS and has unfavorable prog-
nostic value in CAD. (J Am Coll Cardiol 2012;59:1763–70) © 2012 by the American College of Cardiology
Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.02.017Atrial natriuretic peptide (ANP) is a hormone synthesized
in cardiac atria and released into the circulation exerting
relevant natriuretic, diuretic, and vasodilatory effects (1).
Elevated ANP levels are associated with increased cardio-
vascular risk in the general population (2–4) and with
increased mortality in patients with heart failure, ischemic
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peptide. The latter has been shown to reduce endothelial
cell viability, proliferation and endothelial cell tube forma-
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ANP Gene Variant and CAD May 15, 2012:1763–70tion in vitro and to modulate
common mechanisms underlying
the transition from stable to un-
stable plaque (7). The frequency
of the rs5065 variant in the gen-
eral population ranges from 14%
to 23%, and it has been associ-
ated with increased risk of stroke
and myocardial infarction (MI)
in previous studies (8–11). Nev-
ertheless, the impact of rs5065
variant on susceptibility to de-
velop cardiovascular events has
never been investigated through
a prospective type of approach.
In addition, it is not clear whether
this ANP variant, apart from pre-
disposing to increased incidence of
acute cardiovascular events due to
its actions on mechanisms of
plaque vulnerability, might also af-
fect development of atherosclerotic
disease. In this regard, emerging
biomarkers of vascular atheroscle-
rosis and plaque instability (i.e.,
lipoprotein-associated phospho-
lipase A2 [Lp-PLA2], oxidized
low-density lipoprotein [OxLDL],
and myeloperoxidase [MPO])
(12–14) might help our under-
standing of the real impact of
rs5065 on atherosclerotic plaque
progression/vulnerability.
In the present study we aimed
at: 1) investigating the role of
rs5065 variant on susceptibility
to acute coronary syndrome
(ACS) through the analysis of 2
independent ACS populations and 2 independent cohorts of
stable angina (SA) patients; 2) assessing its effect on coronary
artery disease (CAD)-related outcomes through a prospec-
tive follow-up approach in SA patients; and 3) exploring the
impact of rs5065 on atherosclerotic plaque progression/
instability within the context of ischemic heart disease
through the determination of vascular biomarkers like
Lp-PLA2, OxLDL, and MPO.
Methods
Study population. The study population consisted of
1,004 consecutive Caucasian patients referred to the Car-
diovascular Center OLV Aalst (Belgium) for cardiac cath-
eterization from January 2000 to December 2002 because
of: 1) SA with at least 1 significant coronary stenosis
(diameter 50% as assessed by quantitative coronary an-
Abbreviations
and Acronyms
ACE-I  angiotensin-
converting enzyme
inhibitors
ACS  acute coronary
syndrome(s)
ANP  atrial natriuretic
peptide
BMI  body mass index
CAD  coronary artery
disease
CVA  cerebrovascular
accident
ELISA  enzyme-linked
immunoadsorbent assay
Lp-PLA2  lipoprotein-
associated phospholipase A2
MA  minor allele
MACCE  major adverse
cardiac and
cerebrovascular event(s)
MACE  major adverse
cardiovascular event(s)
MI  myocardial infarction
MPO  myeloperoxidase
NT  N-terminal
OxLDL  oxidized low-
density lipoprotein
rACS  independent
patient population with
acute coronary syndrome
rSA  independent
population of stable angina
patients
SA  stable angina
WT  wild-typegiography) and positive functional stress test; or 2) ACS M(e.g., unstable angina, non–ST-segment elevation MI or
ST-segment elevation MI) (15). Control population con-
sisted of 393 healthy Caucasian volunteers. To replicate the
findings observed in SA patients, genotype analysis was also
performed in an independent population of 482 consecutive
stable angina (rSA) Caucasian patients with at least 1
significant coronary stenosis (diameter 50% as assessed by
quantitative coronary angiography) and positive functional
stress test referred for cardiac catheterization from January
2007 to December 2009. To replicate the findings observed
in ACS patients, genotype analysis was also performed in an
independent population of 675 Caucasian patients with
ACS, originating from the Belgian cohort of the GRACE
registry (Global Registry of Acute Coronary Events) (16).
aucasian ethnicity of the subjects included in the study was
stablished on the basis of a questionnaire to exclude
on-Caucasian origin up to 3 generations of ancestors. Only
hite European subjects and patients from 3 generations of
ncestors were included in the study.
Systemic arterial hypertension was defined as systolic
lood pressure 140 mm Hg and/or diastolic blood pres-
sure 90 mm Hg on at least 2 separate occasions (17) or
ngoing antihypertensive treatment. Diabetes mellitus was
efined as the presence of an active treatment with insulin or
n oral antidiabetic agent (18). Patients were defined as
ypercholesterolemic when they had total cholesterol
lasma concentrations 220 mg/dl or they were receiving
ipid-lowering drugs. Patients reporting regular smoking in
he previous 6 months were considered current smokers.
Clinical endpoints were evaluated at clinic visits alter-
ated with phone contacts for up to 6 years in the SA
opulation and 4 years in the rSA population. The primary
ndpoint was major adverse cardiovascular event (MACE),
efined as the composite of: 1) mortality from all causes
Death); 2) MI; and 3) revascularization by percutaneous
oronary intervention or bypass surgery (Revasc). Secondary
ndpoints were death, MI, revascularization, cerebrovascu-
ar accidents (CVAs), and major adverse cardiac and cere-
rovascular event (MACCE) (composite of death, MI,
evascularization, and CVA).
The study was approved by the Ethical Committees of
he participating institutions, and informed consent was
btained from all subjects.
enetic analysis. A blood sample collection was per-
ormed from a peripheral vein for deoxyribonucleic acid
nalysis. Deoxyribonucleic acid was extracted from whole
lood with a commercially available kit (Qiagen). The ANP
ene single nucleotide polymorphism rs5065 was character-
zed as previously described (8,19).
iomarker assessment. Blood sampling for biomarker as-
essment was performed at the time of study enrolment in
SA patients. The N-terminal (NT)-proANP levels were
ssessed by a commercially available enzyme-linked immu-
oadsorbent assay (ELISA) kit (Gruppe Biomedica,
ienna, Austria). The MPO levels were measured by
ercodia MPO ELISA kit (Mercodia, Uppsala, Sweden);
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Diadexus ELISA kit (Diadexus, South San Francisco,
California); OxLDL levels were determined by a sand-
wich ELISA kit with the monoclonal antibody 4E6
(Mercodia). The antibody 4E6 is especially against an
epitope in the apoB-100 moiety of OxLDL that is
formed from substitution of lysine residues of apoB-100
with aldehydes (20).
Statistical analysis. All data analyses were performed with
PSS software package (version 13.0, SPSS, Inc., Chicago,
llinois). Normal distribution was assessed by Kolmogorov-
mirnov test. Continuous variables are expressed as mean
SD or median [interquartile ranges]; categorical variables
are expressed as frequencies and percentages. Student t test
or Mann-Whitney test was used to compare continuous
variables, as appropriate. Comparisons between categorical
variables were evaluated with 2-tailed Fisher exact test or
Pearson’s chi-square test, as appropriate. The NT-proANP
levels within the different genotypes were compared with
Kruskal-Wallis test. Predictors of biomarkers elevation were
assessed by linear regression analysis for continuous vari-
ables adjusted for age, sex, body mass index (BMI), hyper-
tension, hypercholesterolemia, diabetes, and smoking. Ge-
notype frequencies and Hardy-Weinberg equilibrium were
estimated with chi-square test.
The risk associated with ANP variant in the occurrence
of ACS and risk of significant coronary stenosis at angiog-
raphy were estimated by logistic regression analysis, com-
puting the odds ratio with the respective 95% confidence
interval under the assumption of a dominant model (score of
0 for WT; 1 for heterozygous and double mutant). Due to
the low number of homozygotes for the rs5065 minor allele
(MA), neither additive nor recessive models of inheritance
were included. A multivariate logistic regression analysis
model was built including the following variables as cova-
riates: age, sex, BMI, hypertension, hypercholesterolemia,
diabetes, and smoking.
Survival curves for MACE were constructed with the
Kaplan–Meier method. Clinical endpoints were evaluated
with the Cox proportional hazard analysis. Cox propor-
tional hazard analysis for cumulative MACE at follow-up
was performed with 4 multivariate models: 1) adjusted for
age, sex, BMI, hypertension, diabetes, hypercholesterol-
emia, smoking habit, multivessel disease; 2) adjusted for
age, hypertension, diabetes, hypercholesterolemia, smoking
habit, therapy with angiotensin-converting enzyme inhibi-
tors (ACE-I), diuretic agents, aspirin; 3) adjusted for sex,
hypertension, diabetes, hypercholesterolemia, smoking
habit, therapy with ACE-I, diuretic agents, aspirin; and
4) adjusted for multivessel disease, hypertension, diabetes,
hypercholesterolemia, smoking habit, therapy with ACE-I,
diuretic agents, aspirin. Results are expressed as hazard
ratios (diuretic agents) and 95% confidence intervals. For all
tests, a 2-tailed p  0.05 was considered significant.Results
Clinical characteristics. Clinical characteristics of the pa-
tients are shown in Table 1. With the exception of BMI and
therapy with diuretic agents, clinical features and medical
therapy of patients with SA and ACS were significantly
different as compared with the control population. The SA
patients were characterized with higher frequency of mul-
tivessel disease as compared with ACS.
The rSA patients were younger, with higher incidence of
hypertension and hypercholesterolemia, as compared with
the SA group. By contrast, smoking habit, multivessel
disease, and treatment with ACE-I and aspirin at discharge
were lower as compared with the SA group.
The rACS patients were slightly older and more fre-
quently smokers, whereas they presented with lower fre-
quency of male sex, hypertension, diabetes, and hypercho-
lesterolemia, compared with ACS patients. Medical therapy
also differed at discharge, as compared with ACS patients
(Table 1).
rs5065 ANP gene polymorphism analysis. Genotype and
allele frequency of the patients is reported in Table 1. The
observed genotype distribution for rs5065 in the overall
population was in Hardy-Weinberg equilibrium (p 0.48).
Frequency of the rs5065 MA in control subjects was similar
to that previously published in other control populations
(8,10,16). As shown in Table 1, both SA and rSA patients
presented an rs5065 MA frequency similar to that observed
in control subjects. In contrast, both ACS and rACS
patients presented higher frequency of rs5065 MA, as
compared with control and SA patients.
rs5065 ANP gene polymorphism and circulating bio-
markers. The NT-proANP plasma levels were assessed in
428 rSA patients. No differences were detected among the
3 genotypes: 4,138 (2,988 to 6,578) fmol/ml in rs5065 WT,
4,266 (2,833 to 6,373) fmol/ml in rs5065 heterozygotes,
4,677 (2,531 to 8,137) fmol/ml in rs5065 mutant homozy-
gotes (p  0.92).
The MPO, Lp-PLA2, and OxLDL were assessed in 212
rSA patients (Fig. 1). The MPO levels were significantly
higher in rs5065 MA carriers as compared with WT (597
[345 to 832] g/l vs. 488 [353 to 612] g/l, p  0.038). At
the linear regression analysis, rs5065 MA was the only
independent predictor of MPO elevation (unadjusted:
beta 0.21, t 3.04, p 0.003; adjusted: beta 0.18, t
.66, p  0.008). No significant difference was observed
etween rs5065 WT and rs5065 MA carriers with regard to
p-PLA2 (251 [204 to 311] g/l vs. 252 [215 to 315] g/l,
p  0.59) and OxLDL (60 [43 to 79] U/l vs. 55 [45 to 75]
U/l, p  0.78) levels.
Correlation of rs5065 ANP gene polymorphism with
angiographic and clinical outcome. Predictors of ACS are
shown in Table 2. The multivariate adjusted analysis con-
firmed the rs5065 MA to be an independent predictor of
ACS.
Clinical Characteristics and Genotypes of the Study GroupsTable 1 Clinical Characteristics and Genotypes of the Study Groups
CTRL
(n  393)
SA
(n  432)
p Value
(vs. CTRL)
rSA
(n  482)
p Value
(vs. CTRL)
p Value
(vs. SA)
ACS
(n  572)
p Value
(vs. CTRL)
p Value
(vs. SA)
rACS
(n  675)
p Value
vs. CTRL
p Value
vs. ACS
Age, yrs 69 13 76 10 0.001 65 11 0.001 0.001 64 12 0.001 0.001 66 12 0.001 0.037
Male 247 (63) 306 (71) 0.017 313 (65) 0.525 0.065 493 (86) 0.001 0.001 507 (75) 0.001 0.001
BMI, kg/m2 26 4 27 4 0.109 27 5 0.01 0.122 27 4 0.121 0.815 27 4 0.147 0.894
Hypertension 164 (42) 222 (51) 0.004 281 (58) 0.001 0.037 362 (63) 0.001 0.001 372 (55) 0.001 0.004
Diabetes 60 (15) 90 (21) 0.037 119 (25) 0.001 0.179 181 (32) 0.001 0.001 127 (19) 0.156 0.001
Hypercholesterolemia 118 (30) 249 (58) 0.001 324 (67) 0.003 0.003 348 (61) 0.001 0.434 289 (43) 0.001 0.001
Smoking habit 115 (29) 197 (46) 0.001 186 (39) 0.003 0.03 277 (48) 0.001 0.482 397 (59) 0.001 0.001
Multivessel disease — 288 (67) — 179 (37) — 0.001 296 (52) — 0.001 360 (50) — 0.538
Genotype 0.522 0.901 0.599 0.002 0.001 0.002 0.703
rs5065 WT 284 (72) 324 (75) 358 (74) 359 (63) 424 (63)
rs5065 heterozygote 103 (26) 99 (23) 109 (23) 198 (35) 238 (35)
rs5065 mutant homozygote 6 (2) 9 (2) 15 (3) 15 (2) 13 (2)
Allele 0.571 0.946 0.637 0.003 0.001 0.005 0.854
WT 671 (85) 747 (86) 825 (86) 916 (80) 1,086 (80)
MA 115 (15) 117 (14) 139 (14) 228 (20) 264 (20)
Treatment at discharge
Beta-blockers 91 (23) 203 (47) 0.001 253 (52) 0.001 0.098 326 (57) 0.001 0.002 475 (70) 0.001 0.001
ACE-I 143 (36) 186 (43) 0.054 163 (34) 0.434 0.004 332 (58) 0.001 0.001 405 (60) 0.001 0.488
Diuretic agents 117 (30) 112 (26) 0.243 120 (25) 0.109 0.761 194 (34) 0.183 0.007 —
Calcium antagonists 41 (10) 69 (16) 0.0238 73 (15) 0.043 0.784 132 (23) 0.001 0.005 —
Statins 99 (25) 259 (60) 0.001 287 (60) 0.001 0.946 463 (81) 0.001 0.001 391 (58) 0.001 0.001
Aspirin 108 (27) 384 (89) 0.001 338 (70) 0.001 0.001 543 (95) 0.001 0.001 589 (87) 0.001 0.001
Values are mean  SD or n (%). Fisher or chi-square test performed as appropriate.
ACE-I  angiotensin-converting enzyme inhibitors; ACS  acute coronary syndrome(s); BMI  body mass index; CTRL  control; MA  minor allele; rACS  independent patient population with acute coronary syndrome; rSA  independent population of stable angina
patients; SA  stable angina; WT  wild-type.
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May 15, 2012:1763–70 ANP Gene Variant and CADThe rs5065 variant neither showed an effect on the risk of
significant coronary artery stenosis at the angiography (p 
0.15) nor was associated with the number of diseased vessels
(p  0.32).
In SA patients, median clinical follow-up was 37 months
(13 to 70 months), and it was obtained in 376 patients
(87%). A total of 145 (39%) patients experienced MACE
during the follow-up period (Table 3). At the univariate
analysis, MA carriers showed a significantly higher rate of
MI, the combined endpoint of death/MI, revascularization,
MACCE, and MACE as compared with WT (Table 3).
No difference was observed in the rate of death and CVA.
Figure 1 Biomarkers in rs5065 Homozygotes
and in MA Carriers
Myeloperoxidase (MPO), lipoprotein-associated phospholipase A2 (Lp-PLA2),
and oxidized low-density lipoprotein (OxLDL) plasma levels in rs5065 WT (WT)
(green) versus minor allele (MA) carriers (blue). The OxLDL was determined by
4E6 Mercodia antibody (Mercodia, Uppsala, Sweden).Survival analysis revealed a significantly lower MACE-freesurvival in MA carriers (Fig. 2A). At Cox proportional
hazard analysis, irrespective of the multivariate model,
rs5065 MA carriers were independently associated with
significantly higher MACE rate at follow-up (Table 4).
Medical treatment at follow-up did not significantly differ
between rs5065 WT and MA carriers (data not shown),
with the exception of diuretic agents. In particular, 123
(24%) WT patients and 156 (30%) rs5065 MA carriers were
taking diuretic agents (p  0.02).
In rSA patients, median clinical follow-up was 31 months
(23 to 41 months), and it was obtained in 462 patients
(96%). A total of 86 (19%) patients experienced MACE
during the follow-up period (Table 3). At the univariate
analysis, MA carriers showed a significantly higher rate of
MI, the combined endpoint of death/MI, CVA, MACCE,
and MACE as compared with WT (Table 3). No difference
was observed in the rate of death and Revasc. Survival
analysis revealed a significantly lower MACE-free survival
in MA carriers (Fig. 2B). At Cox proportional hazard
analysis, irrespective of the multivariate model, rs5065 MA
carriers were independently associated with significantly
higher MACE rate at follow-up (Table 4). Medical treat-
ment at follow-up did not significantly differ between WT
and MA carriers (data not shown).
Discussion
Our findings demonstrate that patients carrying the rs5065
MA are at higher risk of ACS and show lower MACE-free
survival rate.
The ANP variant resulting from a T to C substitution at
position 2238 of the pre-proANP gene is present in 14% to
23% of individuals from the general population (8,21). It
leads to a mutant peptide able to induce endothelial cell
damage by increasing reactive oxygen species production
and reducing antioxidative stress response (7). This mutant
peptide was also shown to up-regulate genes encoding
enzymes involved in extracellular matrix degradation that
might favor the transition from stable to unstable plaque (7).
The rs5065 ANP variant has been previously associated
with increased risk of stroke and MI (8–11). In the present
study, we demonstrate increased frequency of rs5065 MA in
ACS patients, with a nearly 2-fold independent risk of
Predictors of ACS at Multivariate AnalysisTable 2 Predictors of ACS at Multivariate Analysis
OR 95% CI p Value
rs5065 MA 1.90 1.40–2.58 0.001
Hypertension 1.85 1.37–2.49 0.001
Diabetes 1.68 1.21–2.33 0.002
Age 0.91 0.89–0.92 0.001
Smoking 0.69 0.50–0.96 0.028
BMI 0.96 0.93–0.99 0.015
Hypercholesterolemia 0.75 0.56–1.01 0.062
Male 0.99 0.70–1.41 0.98Patients from SA and ACS populations.
CI  confidence interval; OR  odds ratio; other abbreviations as in Table 1.
ined de
s vent (d
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cardiovascular events of rs5065 MA is supported by the
observation of lower event free survival with higher MI and
higher combined death/MI, revascularization, MACCE,
and MACE rates in SA patients carrying rs5065 MA. Yet,
no association of rs5065 MA with significant coronary
artery stenosis or with the number of diseased vessels was
observed. This apparent discrepancy might be related to the
reported in vitro effects of this ANP variant favoring plaque
instability (7).
Of note, elevated MPO levels were measured in MA
carriers, as compared with WT subjects, in rSA patients,
consistent with a major effect on plaque vulnerability rather
than on progression of vascular atherosclerosis. Myeloper-
oxidase seems to play a causal role in plaque instability (22)
by exerting its deleterious effects through: 1) the initiation of
lipid oxidation in the subendothelial space of the vessel wall,
where it generates several reactive oxygen intermediates able
to induce oxidative cellular damage; and 2) the activation of
matrix metalloproteinases (23) and deactivation of matrix
metalloproteinase inhibitors (24), thereby promoting the
weakening of the fibrous cap, potentially leading to desta-
bilized atherosclerotic plaque. Myeloperoxidase has been
Association of rs5065 MA With MI and MACE at Follow-UpTable 3 Association of rs5065 MA With MI and MACE at Follo
SA Population
WT MA Carriers HR (95% CI) p
Death 13 (4) 3 (6) 1.73 (0.49–6.09)
MI 26 (8) 14 (27) 4.02 (2.10–7.71) 
Death/MI 39 (12) 17 (34) 3.26 (1.84–5.77) 
Revasc 101 (31) 25 (47) 1.81 (1.16–2.79)
CVA 6 (2) 1 (2) 1.15 (0.14–9.58)
MACCE 117 (36) 31 (60) 1.94 (1.30–2.88)
MACE 114 (35) 31 (60) 2.85 (1.56–5.24) 
Values are n (%). Univariate analysis.
HR hazard ratio; MACCEmajor adverse cardiac and cerebrovascular event (defined as comb
urgery [Revasc], and cerebrovascular accidents [CVAs]); MACE  major adverse cardiovascular e
Figure 2 Survival Curves in Stable Angina and Independent Sta
(A) Major adverse cardiovascular event (MACE)-free survival (mortality from all cau
bypass surgery) in stable angina population (log-rank: 6.13, p  0.013). (B) MACE
cutaneous coronary intervention or bypass surgery) in an independent population o
cated with green line, patients carrying rs5065 MA are indicated with blue line.associated with higher risk of developing first acute coronary
event as well as subsequent cardiovascular events in patients
previously admitted for ACS (25,26). Although we cannot
clarify the causal interaction between mutant ANP and
MPO levels, we suggest that MPO might act synergistically
and exacerbate the effects of mutant ANP in CAD patients.
By contrast, we did not observe any association between
rs5065 MA and levels of either OxLDL or Lp-PLA2. Lack
of association with these 2 biomarkers could be partly
explained by their involvement mostly in the progression,
severity, and extent of atherosclerotic disease rather than on
plaque vulnerability (27–30). However, with regard to our
findings on OxLDL, it should also be mentioned that the
4E6 antibody from Mercodia used in our assay does not
have a high specificity for OxLDL, being especially pre-
pared against an epitope in the apoB-100 moiety of OxLDL
(31,32), and consequently, it might have limited, at least in
part, the results of our analysis.
Data in SA patients were replicated in an independent
control patient population (rSA). It should be acknowl-
edged that rSA patients showed lower MACEs as com-
pared with SA patients (19% vs. 39%, p  0.001), most
likely due to different duration of follow-up, lower incidence
rSA Population
p ValueWT MA Carriers HR (95% CI)
18 (5) 5 (4) 0.78 (0.28–2.16) 0.635
0 (0) 10 (8) 65.09 (3.78–1121) 0.001
18 (5) 15 (12) 2.57 (1.25–5.28) 0.008
36 (10) 19 (16) 1.59 (0.88–2.91) 0.122
1 (0) 6 (5) 16.87 (2.03–140.27) 0.009
55 (16) 37 (31) 2.33 (1.43–3.77) 0.001
54 (16) 32 (27) 1.94 (1.18–3.19) 0.008
ath, myocardial infarction [MI], revascularization by percutaneous coronary intervention or bypass
efined as combined death, MI, and Revasc); other abbreviations as in Tables 1 and 2.
ngina Patient Populations
yocardial infarction, revascularization by percutaneous coronary intervention or
survival (mortality from all causes, myocardial infarction, revascularization by per-
le angina patients (log-rank: 5.71, p  0.017). Patients WT at rs5065 are indi-w-Up
Value
0.392
0.001
0.001
0.008
0.895
0.001
0.001ble A
ses, m
-free
f stab
, hyper
CE-I, di
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May 15, 2012:1763–70 ANP Gene Variant and CADof multivessel disease, and adoption of drug-eluting stents,
unavailable at the time SA patients were recruited. Never-
theless, rSA patients carrying rs5065 MA showed signifi-
cantly higher MI, CVA, MACCE, and MACE rates as
well as lower MACE-free survival at follow-up, as com-
pared with WT patients.
Data in ACS patients were also replicated in an indepen-
dent patient population (rACS). It will be interesting in the
future to assess whether rs5065 ANP variant might influ-
ence cardiovascular prognosis after acute coronary events.
A recent pharmacogenetic study has shown beneficial
effects of treatment with diuretic agents in rs5065 MA
carriers in terms of improved blood pressure control and
reduced cardiovascular risk in hypertensive subjects (21).
Thus, it is possible that a pharmacogenetic interaction
might have slightly confounded our findings at least in SA
patients, because rs5965 MA carriers took diuretic agents
more frequently, as compared with WT patients. Therefore,
the outcome of MA carriers might have been slightly
improved, although it remained significantly worse as com-
pared with that of WT patients.
We also tested the hypothesis that rs5065 ANP variant
might produce its effects through an alteration of the
circulating peptide levels. In fact, a substantial amount of
evidence has shown that elevated ANP levels are associated
with increased cardiovascular risk and with worse prognosis
in patients affected by cardiovascular diseases (1). In partic-
ular, elevated NT-proANP levels were found to parallel the
progression of coronary atherosclerosis (33). High ANP
levels were reported in stroke (6,34), and they have been
associated with increased post-stroke and post-MI mortality
(6) as well as with mortality in heart failure patients (5).
However, we were unable to identify significant differences
among the 3 rs5065 genotypes in terms of circulating
peptide concentrations. Although we cannot exclude a role
of the ongoing medical therapy, the latter finding mainly
suggests that the structural peptide alteration dependent
from the T to C transition within exon 3 of pre-proANP
gene is the predominant cause of the observed increased
predisposition to ACS, consistent with our in vitro obser-
vations (7).
Conclusions
The rs5065 ANP variant leading to altered and dysfunc-
tional ANP peptide is associated with higher risk of ACS
Cox Proportional Hazard Analysis for the Association of rs5065 MATable 4 Cox Proportional Hazard Analysis for the Association o
Model 1 Model 2
HR (CI) p Value HR (CI) p V
SA 1.99 (1.32–2.99) 0.001 2.02 (1.35–3.02) 0.0
rSA 1.82 (1.16–2.87) 0.009 1.73 (1.07–2.79) 0.0
Model 1: adjusted for age, sex, BMI, hypertension, diabetes, hypercholesterolemia, smoking habit
habit, therapy with ACE-I, diuretic agents, aspirin; Model 3: adjusted for sex, hypertension, diabetes
multivessel disease, hypertension, diabetes, hypercholesterolemia, smoking habit, therapy with Aand translates into worse long-term clinical follow-up in SApatients. Our prospective study provides the first demon-
stration of the important predictive role played by rs5065
ANP gene variant in CAD. We measured higher MPO
levels, a biomarker associated with plaque vulnerability, in
rs5065 MA carriers, corroborating previous in vitro evi-
dence of a dysfunctional peptide.
More studies are needed to define whether systematic
screening for ANP gene variants in CAD patients will help
to better define the individual cardiovascular risk prediction.
In particular, more aggressive and specifically tailored phar-
macological treatment might be required to improve clinical
outcome in patients carrying rs5065 MA.
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